-+ 0.00%
-+ 0.00%
-+ 0.00%

Innovent’s Gastric Cancer Drug Meets Dual Survival Endpoints in Phase 3 Trial

PUBT·10/23/2026 12:04:07
Listen to the news
Innovent’s Gastric Cancer Drug Meets Dual Survival Endpoints in Phase 3 Trial
  • Innovent Biologics announced Oct. 23, 2026, that arcotatug tavatecan met both Phase 3 survival endpoints in previously treated, CLDN18.2-positive advanced gastric cancer.
  • Median overall survival reached 10.2 months with the drug versus 6.9 months with physician-selected treatment.
  • Median progression-free survival was 7.1 months versus 3.1 months in the control group.
  • The confirmed objective response rate reached 37.4%, compared with 7.7% for physician-selected treatment.
  • Grade 3 or higher treatment-related adverse events occurred in 47.4% of drug recipients versus 55.9% of controls.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN79743) on October 23, 2026, and is solely responsible for the information contained therein.